XORTX Therapeutics Submits Clinical Trial Application To Conduct Study on PharmacoKinetics
XORTX Therapeutics Inc., a pharmaceutical therapeutics company that is focusing on the development of the innovative therapies for the purpose of treating the progressive kidney disease announced that, it has submitted a clinical trial application (CTA) along with the Health Canada for a study of XRX-OXY-101 bridging pharmacokinetics. The XRX-OXY-101 Bridging Pharmacokinetics Study has been […]
Continue Reading